Our Phone
Since the Janice McArdle Cancer Research Foundation was founded in 2010, we have made it our number one mission to raise money in order to contribute to innovative research and creating greater awareness for early detection of non-smoking related Lung Cancer.
Below you can view highlights of the grants we have awarded by the Janice McArdle Cancer Research Foundation:
Below you can view highlights of the grants we have awarded by the Janice McArdle Cancer Research Foundation:
2012
In 2012, Jannie’s Hope contributed twice to LUNGevity:
RECIPIENT: Laurne Byers, M.D., University of Texas MD Anderson Cancer Center
FOCUS: PARP1 as a Novel Therapeutic Target is Small Cell Lung Cancer
RECIPIENT: Mohamed Hassanein, Ph.D., Vanderbilt University Medical Center
FOCUS: Developing New Non-Invasiv Methods for the Diagnosis of Lung Cancer
2012 Research Grant $50,000
For more information, go to LUNGevity.
RECIPIENT: Laurne Byers, M.D., University of Texas MD Anderson Cancer Center
FOCUS: PARP1 as a Novel Therapeutic Target is Small Cell Lung Cancer
RECIPIENT: Mohamed Hassanein, Ph.D., Vanderbilt University Medical Center
FOCUS: Developing New Non-Invasiv Methods for the Diagnosis of Lung Cancer
2012 Research Grant $50,000
For more information, go to LUNGevity.
2011
RECIPIENT: Dr. Neal Kassel; University of Virginia
FOCUS: For the development of ultrasound technology for treating metastatic brain tumors. Metastatic brain tumors are a common site for primary lung cancer. This technology has shown to be very successful in early studies and is about to begin human trials soon.
For more information, go to Focused Ultrasound Foundation.
FOCUS: For the development of ultrasound technology for treating metastatic brain tumors. Metastatic brain tumors are a common site for primary lung cancer. This technology has shown to be very successful in early studies and is about to begin human trials soon.
For more information, go to Focused Ultrasound Foundation.
RECIPIENT: Dr. Ravi Salgia, University of Chicago
FOCUS: Enormous progress has ben made in recognizing that many non-smoking lung cancers are predisposed by chromosomal mutations. There are screenings already developed and many more in development for detecting these mutations. A targeted therapy can then be devised to treat or possibly even prevent specific lung cancers The most notable treatment to date is crizontinib, a targeted treatment for specific chromosomal mutation ALK.
For more information, go to The University of Chicago Medical Center.
2010
RECIPIENT: Dr. Joseph Salma, Duke University Medical Center
FOCUS: Research supporting development of a special optical device for direct view of lung tumors to determine changes over time. This will help identify aggressive tumors from non-aggressive tumors and development treatment protocols for each patient.
For more information, go to www.dukehealth.org
